{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:59:35Z","timestamp":1783641575370,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MSD Spain","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05742-3","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T21:54:31Z","timestamp":1619560471000},"page":"3979-3988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry"],"prefix":"10.1007","volume":"40","author":[{"given":"Manuel","family":"Pombo-Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Sanchez-Piedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Garcia-Magall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Manrique-Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mart\u00edn-Dom\u00e9nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Colazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"del Pino-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cea-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"D\u00edaz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"9","key":"5742_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1759720X18793317","volume":"10","author":"Z Tahir","year":"2018","unstructured":"Tahir Z, Kavanaugh A (2018) The role of golimumab in inflammatory arthritis. A review of the evidence. Ther Adv Musculoskelet Dis 10(9):181\u2013194","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"12","key":"5742_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J (2016) Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 43(12):2120\u20132130","journal-title":"J Rheumatol"},{"issue":"5","key":"5742_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027456","volume":"9","author":"K Luttropp","year":"2019","unstructured":"Luttropp K, Dozier M, Justo N, Cornillie F, Kachroo S, Govoni M, Salomonsson S, Black CM, Khalifa A (2019) Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open 9(5):e027456","journal-title":"BMJ Open"},{"issue":"4","key":"5742_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL (2016) Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken) 68(4):432\u2013439","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5742_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-018-4324-7","volume":"38","author":"\u017d Rotar","year":"2019","unstructured":"Rotar \u017d, Tom\u0161i\u010d M, Praprotnik S, Slovenian Rheumatologists (2019) The persistence of golimumab compared to other tumour necrosis factor-\u03b1 inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clin Rheumatol 38(2):297\u2013305","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5742_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74(4):757\u2013761","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5742_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC (2016) Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken) 68(6):744\u2013752","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5742_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3899\/jrheum.150712","volume":"43","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC (2016) Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol 43(2):298\u2013306","journal-title":"J Rheumatol"},{"issue":"3","key":"5742_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","volume":"39","author":"MV Hernandez","year":"2019","unstructured":"Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, Martin-Domenech R, Del Pino-Montes J, Manrique S, Castro-Villegas MC, Ruiz-Montesinos D, Sanchez-Alonso F, Diaz-Gonzalez F, Cea-Calvo L, G\u00f3mez-Reino JJ, BIOBADASER Study Group (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509\u2013515","journal-title":"Rheumatol Int"},{"issue":"Suppl 2","key":"5742_CR10","first-page":"ii13","volume":"63","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Dewitt EM (2004) Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 63(Suppl 2):ii13\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"5742_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/PPA.S128665","volume":"11","author":"A Svedbom","year":"2017","unstructured":"Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A (2017) Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer Adherence 11:719\u2013729","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"5742_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-015-0516-6","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Kay J, Doyle M, Landew\u00e9 R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC (2015) Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor \u03b1 inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther 17(1):14","journal-title":"Arthritis Res Ther"},{"key":"5742_CR13","first-page":"141","volume":"42","author":"AF Mour\u00e3o","year":"2017","unstructured":"Mour\u00e3o AF, Ribeiro C, Borges J, Gon\u00e7alves MJ, Bernardes M, Fernandes S, Dezerto R, Laires P, Machado P, Eus\u00e9bio M, Santos MJ, Canh\u00e3o H (2017) Real-life effectiveness of golimumab in biologic-na\u00efve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt). Acta Reumatol Port 42:141\u2013149","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"5742_CR14","first-page":"804","volume":"35","author":"M Manara","year":"2017","unstructured":"Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi Puttini P, Gorla R, Bazzani C, Fusaro E, Pellerito R, Rocchetta PA, Sinigaglia L (2017) Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol 35(5):804\u2013809","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5742_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D'Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47(1):108\u2013114","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5742_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/1756-185X.13199","volume":"21","author":"EG Favalli","year":"2018","unstructured":"Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R (2018) Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis 21(2):422\u2013430","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"5742_CR17","first-page":"254","volume":"36","author":"K Thomas","year":"2018","unstructured":"Thomas K, Flouri I, Repa A, Fragiadaki K, Sfikakis PP, Koutsianas C, Kaltsonoudis E, Voulgari PV, Drosos AA, Petrikkou E, Sidiropoulos P, Vassilopoulos D (2018) High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clin Exp Rheumatol 36(2):254\u2013262","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5742_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/03009742.2016.1234641","volume":"46","author":"KJ Aaltonen","year":"2017","unstructured":"Aaltonen KJ, Joensuu JT, Piril\u00e4 L, Kauppi M, Uutela T, Varjolahti-Lehtinen T, Yli-Kerttula T, Isom\u00e4ki P, Nordstr\u00f6m D, Sokka T (2017) Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol 46(5):359\u2013363","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"5742_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2019.07.003","volume":"50","author":"B Michelsen","year":"2020","unstructured":"Michelsen B, Sexton J, Wier\u00f8d A, Bakland G, R\u00f8devand E, Kr\u00f8ll F, Kvien TK (2020) Four-year follow-up of inflammatory arthropathy patients treated with golimumab: data from the observational multicentre NOR-DMARD study. Semin Arthritis Rheum 50(1):12\u201316","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"5742_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","volume":"71","author":"JD Greenberg","year":"2012","unstructured":"Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM, CORRONA Investigators (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71(7):1134\u20131142","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5742_CR21","first-page":"1737","volume":"35","author":"SK Agarwal","year":"2008","unstructured":"Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH (2008) Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 35(9):1737\u20131744","journal-title":"J Rheumatol"},{"key":"5742_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","volume":"10","author":"J Mahlich","year":"2016","unstructured":"Mahlich J, Sruamsiri R (2016) Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence 10:1509\u20131519","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"5742_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jbspin.2019.09.017","volume":"87","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Belhassen M, Hudry C, Woronoff-Lemsi MC, Levy-Bachelot L, Van Ganse E, Tubach F (2020) Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: an observational study in 8052 patients. Joint Bone Spine 87(3):267\u2013269","journal-title":"Joint Bone Spine"},{"key":"5742_CR24","doi-asserted-by":"crossref","unstructured":"Ca\u00f1ete JD, Naranjo A, Calvo J, Ord\u00e1s C, Arag\u00f3n B, Nocea G, Roset M, Fern\u00e1ndez-Nebro A (2019) Biological treatment patterns in patients with inflammatory joint diseases. Retrospective study with 4 years follow-up. Reumatol Clin S1699-258X(18)30259-6","DOI":"10.1016\/j.reumae.2018.11.016"},{"issue":"9","key":"5742_CR25","doi-asserted-by":"publisher","first-page":"e015872","DOI":"10.1136\/bmjopen-2017-015872","volume":"7","author":"P Bhoi","year":"2017","unstructured":"Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K (2017) Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open 7(9):e015872","journal-title":"BMJ Open"},{"issue":"4 Suppl 1","key":"5742_CR26","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","volume":"38","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38(4 Suppl 1):S2\u2013S6","journal-title":"Bone"},{"issue":"3","key":"5742_CR27","first-page":"423","volume":"35","author":"J Calvo-Al\u00e9n","year":"2017","unstructured":"Calvo-Al\u00e9n J, Monteagudo I, Salvador G, V\u00e1zquez-Rodr\u00edguez TR, Tovar-Beltr\u00e1n JV, Vela P, Maceiras F, Bustabad S, Rom\u00e1n-Ivorra JA, D\u00edaz-Miguel C, Rosas J, Raya E, Carmona L, Cea-Calvo L, Arteaga MJ, Fern\u00e1ndez S, Marras C (2017) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 35(3):423\u2013430","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"5742_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s10067-018-4105-3","volume":"37","author":"K Tymms","year":"2018","unstructured":"Tymms K, Littlejohn G, Griffiths H, de Jager J, Bird P, Joshua F, Nash P, Handel M, McManus H, Butcher BE, Youssef P (2018) Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clin Rheumatol 37(6):1617\u20131623","journal-title":"Clin Rheumatol"},{"issue":"2","key":"5742_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semarthrit.2017.03.010","volume":"47","author":"GS Calip","year":"2017","unstructured":"Calip GS, Adimadhyam S, Xing S, Rincon JC, Lee WJ, Anguiano RH (2017) Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum 47(2):157\u2013164","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5742_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.clinthera.2014.02.019","volume":"36","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36(5):737\u2013747","journal-title":"Clin Ther"},{"issue":"7","key":"5742_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S (2016) Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int 36(7):987\u2013995","journal-title":"Rheumatol Int"},{"key":"5742_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/PPA.S186776","volume":"13","author":"P Takacs","year":"2019","unstructured":"Takacs P, Lathia U, Shin J, Nantel F (2019) Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis. Patient Prefer Adherence 13:157\u2013163","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"5742_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","volume":"57","author":"C Stober","year":"2018","unstructured":"Stober C, Ye W, Guruparan T, Htut E, Clunie G, Jadon D (2018) Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 57(1):158\u2013163","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5742_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","volume":"45","author":"ID Flouri","year":"2018","unstructured":"Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P (2018) Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. J Rheumatol 45(6):785\u2013794","journal-title":"J Rheumatol"},{"issue":"3","key":"5742_CR35","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, G\u00f3mez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford) 55(3):523\u2013534","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5742_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU, GO-FORWARD Study (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789\u2013796","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5742_CR37","first-page":"422","volume":"37","author":"CB McCulley","year":"2019","unstructured":"McCulley CB, Barton JL, Cannon GW, Sauer BC, Teng CC, George MD, Caplan L, England BR, Mikuls TR, Baker JF (2019) Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol 37(3):422\u2013428","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5742_CR38","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13(5):e0195123","journal-title":"PLoS One"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05742-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T06:08:07Z","timestamp":1632550087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05742-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5742"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05742-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Manuel Pombo-Suarez: consulting fee from MSD; Blanca Garcia-Magall\u00f3n: payments for consultancy, lectures, presentations, or travel expenses by MSD, Pfizer, Bristol-Myers, Amgen, Celgene, and Menarini; Sara Manrique-Arija: payments for consultancy, lectures, presentations, or travel expenses by Abbvie, Janssen, Sanofi, Novartis, Pfizer, Lilly, MSD, and Menarini; Jos\u00e9 Campos: payments for consultancy, lectures, presentations, or travel expenses by Pfizer, MSD, Novartis, Lilly, Roche, and Sanofi; Maria J. Arteaga: full-time employee at Medical Affairs, MSD, Spain; Luis Cea-Calvo: full-time employee at Medical Affairs, MSD, Spain; Federico D\u00edaz-Gonz\u00e1lez: grant from MSD; Juan J. G\u00f3mez-Reino: payments for consultancy, lectures, and grants from MSD. The rest of the authors declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed informed consent to be included in the BIOBADASER registry. Informed consent included consent for subsequent analysis, such as in the present analysis. Patients\u2019 information was managed as anonymized aggregated data, and as approved by the Clinical Research Committee, specific informed consent for this analysis was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}